Ansa Biotechnologies, Inc., a trusted partner for DNA synthesis, today announced that it has closed $45.2 million and secured commitments for an additional $9.2 million as part of an oversubscribed series B financing round. The round was led by Cerberus Ventures with participation from Blue Water Life Science Advisors, Altitude Life Science Ventures, and other existing investors. New investors include Fall Line Capital, AIM13, and Black Opal Ventures.
As part of the financing, Chenny Zhang, Director at Cerberus Ventures, and Yanniv Dorone, PhD, Senior Vice President at Fall Line Capital, joined Ansa’s board of directors. They offer diverse industry experience and extensive technical expertise in key application fields, aiding Ansa’s long-term strategic goals.
Read More – OncoC4 Raises Nearly $50M in Series B Funding
The proceeds from this financing will enable Ansa to expand its U.S.-based manufacturing capacity, enhance its focus on customer experience, and continue to advance strategic relationships and technological innovation. These efforts will allow Ansa to introduce novel applications, help customers accelerate their scientific progress at unprecedented speeds, and support the industry’s shift from reading genomes to writing them.
“Ansa is leading a fundamental shift in DNA synthesis,” said Ms. Zhang. “For decades, the market has been limited by an unreliable and outdated process. Ansa’s management team has done an excellent job demonstrating that scientists can finally get what they need, when they need it. We believe Ansa’s guaranteed approach fills a huge unmet need, and should become the new standard for DNA synthesis.”
Transforming DNA Synthesis
Chemical DNA synthesis was foundational to the DNA reading era of biology, but it poses significant limitations as the industry transitions into the DNA writing era. The inability to reliably synthesize complex sequences or reach beyond modest lengths has stalled progress just as science is ready to move forward.
Ansa is redefining what is achievable with a proprietary enzymatic platform that provides both the length and complexity needed to design and assemble critical DNA constructs at scale. Unlike traditional chemical synthesis, Ansa’s sustainable enzymatic approach uses no harsh chemicals, preserving DNA integrity and enabling the synthesis of longer, more complex sequences. This capability unlocks previously inaccessible regions of the genome, empowering scientists to build new pathways, engineer innovative systems, and accelerate discoveries in gene and cell therapy, vaccines, agrigenomics, and synthetic biology.
Read More – Cyvl Raises $14M in Series A Funding
